Sutter Health Hospitals Deploy Wearable Ultrasound Tech to Personalize Fluid Management for Sepsis
IV fluid overload is a common complication in emergency and intensive care settings, in part because predicting a patient's response to fluids is complex. Individual needs can vary widely and shift quickly during critical illness. In studies of patients with sepsis and septic shock – a life-threatening condition caused by the body's overwhelming response to infection – nearly one-third were found to be fluid unresponsive¹. Without early identification of fluid unresponsiveness, patients may receive excessive fluids, increasing their risk of serious complications such as pulmonary edema, where fluid accumulates in the lungs. By some estimates, fluid overload can extend the average hospital stay by three days and increase healthcare costs by more than $15,000 per patient².
FloPatch is an FDA-cleared, wearable device that provides clinicians with a fast and non-invasive way to perform hemodynamic assessments, measuring a patient's heart and blood flow response to IV fluids to help guide personalized fluid therapy. Clinical studies have shown that dynamic fluid assessments can reduce the need for mechanical ventilation and renal replacement therapy³,⁴, decrease ICU length of stay⁴, and are associated with lower mortality⁵.
'Our previous method of assessing fluid responsiveness was cumbersome and time-consuming. We often had to pull ICU nurses to perform evaluations in other units, which was disruptive and inefficient,' said Dr. Nader Emami, ICU medical director at Sutter Santa Rosa Regional Hospital. 'FloPatch streamlines the process with a simple, wearable device that empowers any member of the care team to perform this essential assessment faster and easier.'
'In emergency care, we often treat patients with complex needs, including people with sepsis,' said Dr. John Skovran, Emergency Department medical director at Sutter's Alta Bates Summit Medical Center, Summit Campus. 'We need a fast, reliable way to determine whether they'll benefit from fluids or be harmed by them. FloPatch gives us that clarity at the bedside in minutes, helping us make confident, timely decisions.'
Joe Eibl, chief executive officer and co-founder of Flosonics Medical, noted: 'Sutter Health's multisite adoption of FloPatch reflects a growing recognition that wearable, real-time technologies play a transformative role in patient care. It's a great example of how forward-thinking health systems are meeting critical challenges with innovation.'
Sutter Health prioritized staff training and thoughtfully integrated FloPatch into clinical workflows to make it a seamless part of care in intensive care and emergency medicine departments.
About Sutter Health:
Sutter Health is a not-for-profit healthcare system dedicated to providing comprehensive care throughout California. Committed to health equity, community partnerships, and innovative, high-quality patient care, Sutter Health is pursuing a bold new plan to reach more people and make excellent healthcare more connected and accessible. Currently serving more than 3.5 million patients, thanks to our dedicated team of more than 60,500 employees and clinicians, and 14,000+ physicians and advanced practice clinicians, with a unified focus on expanding care to serve more patients.
Sutter delivers exceptional and affordable care through its hospitals, medical groups, ambulatory surgery centers, urgent care clinics, telehealth, home health, and hospice services. Dedicated to transforming healthcare, at Sutter Health, getting better never stops.
Learn more about how Sutter Health is transforming healthcare at sutterhealth.org and vitals.sutterhealth.org.
About Flosonics Medical:
Flosonics Medical is a medical device company engaged in the research and development of innovative ultrasound technology. Founded in 2015, the company's mission is to improve patient care and the practice of medicine through technology-enabled solutions and groundbreaking clinical research. For more information, please visit www.flosonicsmedical.com.
References:
¹ Hernández G, Ospina‑Tascón GA, Damiani LP, et al; ANDROMEDA‑SHOCK Investigators. Effect of a resuscitation strategy targeting peripheral perfusion status vs serum lactate levels on 28‑day mortality among patients with septic shock: the ANDROMEDA‑SHOCK randomized clinical trial. JAMA. 2019 Feb 19;321(7):654–664. doi:10.1001/jama.2019.0071
² American Hospital Directory analysis of FFY2022 Medicare IPPS (MedPAR) claims data
³ Douglas IS, Alapat PM, Corl KA, Exline MC, Forni LG, Holder AL, et al. Fluid Response Evaluation in Sepsis Hypotension and Shock: A Randomized Clinical Trial. Chest. 2020 Oct;158(4):1431–1445. doi:10.1016/j.chest.2020.04.025
⁴ Latham HE, Bengtson CD, Satterwhite L, et al. Stroke volume–guided resuscitation in severe sepsis and septic shock improves outcomes. J Crit Care. 2017 Dec;42:42–46. doi:10.1016/j.jcrc.2017.06.028
⁵ Dubin A, Loudet C, Kanoore Edul VS, et al. Characteristics of resuscitation, and association between use of dynamic tests of fluid responsiveness and outcomes in septic patients: results of a multicenter prospective cohort study in Argentina. Ann Intensive Care. 2020 Apr 15;10(1):40. doi:10.1186/s13613-020-00659-7
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Miami Herald
16 minutes ago
- Miami Herald
A drug carrying the FDA's most serious warning recalled by a Florida company
A pharmaceutical company based in Naples with research and development division based in Coral Springs recalled a drug for failing an in-house testing of medication degradation. Lupin Pharmaceuticals' Clomipramine Hydrochloride capsules are used 'for the treatment of obsessions and compulsions in patients with Obsessive-Compulsive Disorder (OCD),' according to the National Library of Medicine. The 2,724 recalled 100-count bottles of 25 mg capsules come from lot No. M300464 with an expiration date of June 2025. Lupin issued no press release for the June 27 recall. READ MORE: The role fake Viagra played in a 70-year-old Miami doctor losing his license Clomipramine also counts as an antidepressant and carries an FDA 'Black Box Warning' or 'Boxed Warning' on the packaging that begins: 'Antidepressants increased the risk compared to placebo of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults in short-term studies of major depressive disorder (MDD) and other psychiatric disorders. Anyone considering the use of clomipramine hydrochloride or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need.' If you experience a medical problem because of this or any other drug, first notify a medical professional. Then tell the FDA via the MedWatch program, either online or by calling 800-332-1088.
Miami Herald
35 minutes ago
- Miami Herald
Nationwide Ritz Cracker Recall Update as FDA Issues Risk Warning
A nationwide recall of Ritz peanut butter cracker sandwiches over possible undeclared allergens has received the second-highest risk warning by the Food and Drug Administration (FDA). On July 8, Mondelēz Global LLC announced a voluntary recall for various carton sizes of the products as they may have been mislabeled as a cheese variety instead of the peanut version. The FDA issued a Class II risk warning for the recall on July 22. Newsweek contacted Mondelēz Global LLC for comment by email outside regular working hours. A Class II risk classification refers to a situation in which the "use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote," according to the FDA. The agency warned in its recall notice that people with an allergy or severe sensitivity to peanuts "may risk serious or life-threatening allergic reactions by consuming this product." Peanuts are one of the nine major food allergens identified by U.S. law. The others are milk, eggs, fish, crustacean shellfish, tree nuts, wheat, soybeans and sesame. Allergic reactions vary in severity from mild symptoms, such as hives and lip swelling, to life-threatening complications, such as anaphylaxis, that may include fatal respiratory problems. The products affected by the recall include the following: Ritz Peanut Butter Cracker Sandwiches eight-pack, 37,985 cases—with the UPC 0 44000 88210 5 and best-by dates of November 1 to 9, 2025Ritz Peanut Butter Cracker Sandwiches 20-pack, 24,446 cases—with the UPC 0 44000 07584 2 and best-by dates of November 1 to 9, 2025, or January 2 to 22, 2026Ritz Peanut Butter Cracker Sandwiches, 224 cases—with the UPC 0 44000 07819 5 and best-by dates of November 1 to 9, 2025, or January 2 to 22, 2026Ritz Filled Cracker Sandwich 20-count variety pack, 13,872 cases—with the UPC 0 44000 08095 2 and best-by dates of November 2 to 9, 2025 The affected products contain individually wrapped packs that may have been mislabeled as the cheese variety instead of the peanut butter versions, according to the FDA. The incorrect labeling may appear as follows: Ritz Cheese Cracker Sandwiches, with the UPC 0 44000 00211 4 and best-by dates of November 1 to 9, 2025, or January 2 to 22, 2026. The FDA added that all the outer cartons were labeled correctly and indicated the presence of peanuts. The original recall said the affected products were produced in the U.S. and sold at retail stores nationwide. The company initiated the recall after it discovered that film packaging rolls used to wrap individual peanut butter products might "contain defects due to a supplier error." It added, "Corrective actions are being taken to help ensure this issue does not recur." Mondelēz Global LLC said in the July 8 recall notice: "There have been no reports of injury or illness reported to Mondelēz Global LLC to date related to this product, and we are issuing this recall as a precaution." The Food and Drug Administration said on its website: "People with food allergies should read labels and avoid the foods they are allergic to. The law requires that food labels identify the food source of all major food allergens used to make the food." Dr. Sebastian Lighvani, the director of New York Allergy and Asthma PLLC, previously told Newsweek: "Every three minutes in the United States, someone ends up in an emergency room because of an allergic reaction after accidental ingestion of food. So even when we try hard, these reactions are happening. And if you look at the incidence of anaphylaxis, it has skyrocketed in the last five, 10, 20 years. And in the U.S., there's like a 300 to 400 percent increase in the rates of anaphylaxis to foods." The FDA lists the recall as ongoing. Consumers who purchased the affected products and have a peanut allergy should not consume them. Related Articles FDA Issues Risk Warning for Bread Recall UpdateFDA Issues Highest Risk Warning for Tofu RecallCanned Fruit Recall Sparks Nationwide Warning to Customers 2025 NEWSWEEK DIGITAL LLC.
Yahoo
an hour ago
- Yahoo
The 3 Things That Matter for Eli Lilly Now
Key Points Eli Lilly's biggest growth driver, tirzepatide, will continue facing scrutiny from investors and analysts. The company's oral GLP-1 candidate will soon report key phase 3 results in weight management. The drugmaker's shares look expensive, but the premium is justified given Lilly's prospects. 10 stocks we like better than Eli Lilly › Eli Lilly (NYSE: LLY) has been one of the best-performing pharmaceutical leaders in the past five years. Thanks to strong clinical and regulatory progress, as well as robust financial results, the drugmaker has routinely impressed Wall Street. Lilly has experienced a slowdown this year, and its shares have underperformed broader equities. Still, the company could turn things around and return to its market-beating ways, especially if it can execute effectively on several fronts. Let's discuss three critical areas of its business to pay close attention to right now. 1. Tirzepatide's progress It has now been more than three years since the U.S. Food and Drug Administration (FDA) first approved tirzepatide, the medicine Eli Lilly markets as Mounjaro for treating diabetes and as Zepbound for weight management. The two brands have been generating mouthwatering sales. Each racked up billions of dollars in revenue last quarter. Mounjaro and Zepbound will continue to be crucial to Eli Lilly's progress. Here are two key things to watch. First, how quickly are their sales continuing to grow? Analysts will be closely monitoring these numbers for the foreseeable future. Image source: Getty Images. Second, will they earn label expansions? Tirzepatide has already aced other phase 3 studies, such as in cutting the risk of diabetes in patients who were overweight (or obese) and prediabetic. Regulatory authorities are now reviewing it in helping prevent heart failure in obese patients. Tirzepatide is being investigated in late-stage trials as a potential treatment for psoriasis and psoriatic arthritis in combination with other medicines. It's also being tested in mid-stage studies in metabolic dysfunction-associated steatohepatitis (MASH). So the therapy could earn many more label expansions, which will help boost its already fast-growing sales. It's a good idea to monitor Lilly's developments related to this drug. 2. Orforglipron's weight management results In April, Eli Lilly posted strong phase 3 results for its next-gen GLP-1 medicine, orforglipron, in diabetes patients. Orforglipron is a particularly important pipeline candidate to follow, because it could be one of the first oral GLP-1 therapies to hit the market. Some patients don't like needles and would vastly prefer a daily oral option over the current subcutaneously administered options. And while Lilly's recent phase 3 win for orforglipron in diabetes was significant, investors will be especially interested in the medicine's performance in weight management.
